Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €42.19 EUR
Change Today +0.005 / 0.01%
Volume 0.0
NK8 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:00 PM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

nuvasive inc (NK8) Snapshot

Open
€42.24
Previous Close
€42.18
Day High
€42.24
Day Low
€42.10
52 Week High
05/29/15 - €46.51
52 Week Low
07/18/14 - €23.78
Market Cap
2.0B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
48.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NUVASIVE INC (NK8)

nuvasive inc (NK8) Related Businessweek News

No Related Businessweek News Found

nuvasive inc (NK8) Details

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company’s principal product is Maximum Access Surgery (MAS), a minimally-disruptive surgical platform that includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and intra-operative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s biologic product line offerings used to aid the spinal fusion process or bone healing process consist of Osteocel Plus and Osteocel Pro allograft (donated human tissue), which are cellular matrix products containing viable mesenchymal stem cells; FormaGraft, a collagen synthetic product; and AttraX, a synthetic bone graft material. It also provides IOM services for insight into the nervous system during non-spine. The company sells its products through independent sales agencies, directly-employed sales shareowners to surgeons and hospitals in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

1,500 Employees
Last Reported Date: 02/25/15
Founded in 1997

nuvasive inc (NK8) Top Compensated Officers

President and Chief Operating Officer
Total Annual Compensation: $545.7K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $380.5K
President of US Sales and Services
Total Annual Compensation: $375.0K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $454.1K
Consultant
Total Annual Compensation: $900.0K
Compensation as of Fiscal Year 2014.

nuvasive inc (NK8) Key Developments

Nuvasive, Inc. Appoints Vickie L. Capps as Board of Directors

NuVasive, Inc. appointed Vickie L. Capps as a Board of Directors. Ms. Capps will also serve on the Board's Audit Committee and Nominating and Corporate Governance Committee. Her extensive financial expertise and executive leadership experience as a former chief financial officer will provide valuable financial and accounting experience to Board. In addition, Vickie's joining the Board represents another step in further diversifying the depth of experience that resides on Board as the company continually seek to enhance the governance of NuVasive. From July 2002 to December 2013, Ms. Capps served as the Chief Financial Officer of DJO Global, Inc. Prior to joining DJO Global, she served as the Chief Financial Officer of several other public and private companies. Earlier in her career, she served as a senior audit and accounting professional at Ernst &Young LLP. Ms. Capps is a member of the Senior Advisory Board of Consonance Capital Partners, a healthcare investment firm, and serves on the board of its portfolio company, Enclara Pharmacia. She also serves on the board of directors and as chair of the audit committees of RF Surgical Systems, Inc., Otonomy, Inc. and Connecture, Inc. Ms. Capps is a California Certified Public Accountant and was recognized as CFO of the Year by the San Diego Business Journal in 2009 and 2010.

NuVasive, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 08:00 AM

NuVasive, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 08:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

NuVasive, Inc. Presents at Nasdaq 32nd Investor Program, Jun-30-2015 09:30 AM

NuVasive, Inc. Presents at Nasdaq 32nd Investor Program, Jun-30-2015 09:30 AM. Venue: May Fair Hotel, London, United Kingdom.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NK8:GR €42.19 EUR +0.005

NK8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CONMED Corp $58.56 USD -0.18
Globus Medical Inc $25.57 USD -0.26
Integra LifeSciences Holdings Corp $60.53 USD +0.63
Masimo Corp $38.61 USD -0.16
Thoratec Corp $44.19 USD -0.05
View Industry Companies
 

Industry Analysis

NK8

Industry Average

Valuation NK8 Industry Range
Price/Earnings 68.8x
Price/Sales 2.9x
Price/Book 3.5x
Price/Cash Flow 50.1x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVASIVE INC, please visit www.nuvasive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.